Company intelligence / Profile preview
Travere Therapeutics
San Diego, California, United Statesorpha.net ↗
- Ownership
- Public · TVTX
- Employees
- ~385
- Development stage
- Commercial
01
Overview
Travere Therapeutics has received full FDA approval for FILSPARI (sparsentan) to slow kidney function decline in adults with primary IgA nephropathy. The company also has other marketed products including Thiola and Thiola EC for cystinuria treatment.
- Therapeutic areas
- Rare DiseasesMetabolic DisordersNephrology
- Modalities
- Small moleculesEnzyme replacement therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
CSL ViforPharmaKrysto Limited
04
Financials
- Market cap
- $6.2B
- Total revenue
- $169.6M
- Enterprise value
- $6.3B
Beyond the preview
Go deeper on Travere Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Travere Therapeutics.